Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113


Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.

Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, Poulin N, Yi L, Rossi FM, Kast J, Capecchi MR, Underhill TM, Nielsen TO.

Cancer Cell. 2012 Mar 20;21(3):333-47. doi: 10.1016/j.ccr.2012.01.010.


Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.

Carmody Soni EE, Schlottman S, Erkizan HV, Uren A, Toretsky JA.

Clin Orthop Relat Res. 2014 Mar;472(3):874-82. doi: 10.1007/s11999-013-3065-9.


SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.

Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, Renner M, Kirfel J, Steiner S, Huss S, Koch A, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Waha A, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W.

Oncogene. 2014 Oct 16;33(42):5006-16. doi: 10.1038/onc.2013.443. Epub 2013 Oct 28.


Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.

Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de Rijn M, Poulin N, van Kessel AG, Nielsen TO.

Cancer Res. 2008 Jun 1;68(11):4303-10. doi: 10.1158/0008-5472.CAN-08-0092.


Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.

Yoneda Y, Ito S, Kunisada T, Morimoto Y, Kanzaki H, Yoshida A, Shimizu K, Ozaki T, Ouchida M.

PLoS One. 2013 Oct 9;8(10):e77564. doi: 10.1371/journal.pone.0077564. eCollection 2013.


SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas.

Jones KB, Su L, Jin H, Lenz C, Randall RL, Underhill TM, Nielsen TO, Sharma S, Capecchi MR.

Oncogene. 2013 May 2;32(18):2365-71, 2375.e1-5. doi: 10.1038/onc.2012.247. Epub 2012 Jul 16.


The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.

de Bruijn DR, Allander SV, van Dijk AH, Willemse MP, Thijssen J, van Groningen JJ, Meltzer PS, van Kessel AG.

Cancer Res. 2006 Oct 1;66(19):9474-82.


Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.

Kadoch C, Crabtree GR.

Cell. 2013 Mar 28;153(1):71-85. doi: 10.1016/j.cell.2013.02.036.


Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.

Wakamatsu T, Naka N, Sasagawa S, Tanaka T, Takenaka S, Araki N, Ueda T, Nishizawa Y, Yoshikawa H, Itoh K.

Cancer Sci. 2014 Sep;105(9):1124-34. doi: 10.1111/cas.12469. Epub 2014 Sep 3.


Downregulation of SS18-SSX1 expression by small interfering RNA inhibits growth and induces apoptosis in human synovial sarcoma cell line HS-SY-II in vitro.

Peng C, Guo W, Yang Y, Zhao H.

Eur J Cancer Prev. 2008 Oct;17(5):392-8. doi: 10.1097/CEJ.0b013e328305a11b.


SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.

Tamaki S, Fukuta M, Sekiguchi K, Jin Y, Nagata S, Hayakawa K, Hineno S, Okamoto T, Watanabe M, Woltjen K, Ikeya M, Kato T Jr, Toguchida J.

PLoS One. 2015 Nov 16;10(11):e0142991. doi: 10.1371/journal.pone.0142991. eCollection 2015.


The clinical implication of SS18-SSX fusion gene in synovial sarcoma.

Ren T, Lu Q, Guo W, Lou Z, Peng X, Jiao G, Sun Y.

Br J Cancer. 2013 Oct 15;109(8):2279-85. doi: 10.1038/bjc.2013.547. Epub 2013 Sep 10.


Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.

Törnkvist M, Natalishvili N, Xie Y, Girnita A, D'Arcy P, Brodin B, Axelson M, Girnita L.

Biochem Biophys Res Commun. 2008 Apr 11;368(3):793-800. doi: 10.1016/j.bbrc.2008.01.162. Epub 2008 Feb 11.


Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.

Zöllner SK, Rössig C, Toretsky JA.

Cancer Metastasis Rev. 2015 Sep;34(3):417-28. doi: 10.1007/s10555-015-9575-z. Review.


SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.

Minami Y, Kohsaka S, Tsuda M, Yachi K, Hatori N, Tanino M, Kimura T, Nishihara H, Minami A, Iwasaki N, Tanaka S.

Cancer Sci. 2014 Sep;105(9):1152-9. doi: 10.1111/cas.12479. Epub 2014 Sep 3.


Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma.

Amary MF, Berisha F, Bernardi Fdel C, Herbert A, James M, Reis-Filho JS, Fisher C, Nicholson AG, Tirabosco R, Diss TC, Flanagan AM.

Mod Pathol. 2007 Apr;20(4):482-96. Epub 2007 Mar 2.


The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.

Cironi L, Petricevic T, Fernandes Vieira V, Provero P, Fusco C, Cornaz S, Fregni G, Letovanec I, Aguet M, Stamenkovic I.

Sci Rep. 2016 Feb 24;6:22113. doi: 10.1038/srep22113.


The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4.

de Bruijn DR, van Dijk AH, Willemse MP, van Kessel AG.

Oncogene. 2008 Jan 24;27(5):653-62. Epub 2007 Jul 30.


Supplemental Content

Support Center